A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy
Nivolumab, a monoclonal antibody against the programmed cell death protein 1 (PD-1), has shown promising results in patients with advanced malignancies, including melanoma, lung cancer, and renal cancer. Immune-related adverse events (irAEs) have been reported, including both organ-specific toxiciti...
Gespeichert in:
| Veröffentlicht in: | Dermatology online journal 2017-08, Vol.23 (8) |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | |
| container_title | Dermatology online journal |
| container_volume | 23 |
| creator | Elosua-González, Marta Pampín-Franco, Ana Mazzucchelli-Esteban, Ramón Mielgo-Rubio, Xabier Rodriguez-Vásquez, Ximena García-Zamora, Elena López-Estebaranz, Jose Luis |
| description | Nivolumab, a monoclonal antibody against the programmed cell death protein 1 (PD-1), has shown promising results in patients with advanced malignancies, including melanoma, lung cancer, and renal cancer. Immune-related adverse events (irAEs) have been reported, including both organ-specific toxicities and skin toxicities. Herein, we report a case of predominantly palmoplantar psoriasis with severe nail involvement, psoriatic arthritis, and autoimmune hypothyroidism after receiving nivolumab treatment for lung cancer. We also summarize the case reports that have been published previously. The knowledge of these irAEs in patients undergoing anti-PD1 therapy is important since it will enable earlier recognition and appropriate management, with the aim of maintaining effective dose without disruption. |
| doi_str_mv | 10.5070/D3238036018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2007421853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2007421853</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2418-364f69fb47e005441402aadddaf96c93dcebf06c2c8ffd9053ab699f730e49363</originalsourceid><addsrcrecordid>eNpNkMlLxTAQh4Mo7ifvkqMgT6dJuuQo7iB40XOZZrGRtqlJ-uQd_c-tvKd4mYX5-MF8hJxkcJFDCZc3nPEKeAFZtUX2M6jKBZvr9r95jxzE-A7AQOR8l-wxKQpZ5nyffF1RhdFQb6k2dPBLT0fsej92OCQMdIw-OIwu0k-X2s2anKIYUhtcmg84aIpT8q7vp8HQdjX61K6Cd9rFnqJNJtBglHFLN7zRwS19N_XY0NSagOPqiOxY7KI53vRD8np3-3L9sHh6vn-8vnpaKCayasELYQtpG1EagFyITABD1FqjlYWSXCvTWCgUU5W1WkLOsSmktCUHIyQv-CE5W-eOwX9MJqa6d1GZbn7U-CnWDKAULKtyPqPna1QFH2Mwth6D6zGs6gzqH-f1P-czfboJnpre6D_2VzL_Bkqzfv0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2007421853</pqid></control><display><type>article</type><title>A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Elosua-González, Marta ; Pampín-Franco, Ana ; Mazzucchelli-Esteban, Ramón ; Mielgo-Rubio, Xabier ; Rodriguez-Vásquez, Ximena ; García-Zamora, Elena ; López-Estebaranz, Jose Luis</creator><creatorcontrib>Elosua-González, Marta ; Pampín-Franco, Ana ; Mazzucchelli-Esteban, Ramón ; Mielgo-Rubio, Xabier ; Rodriguez-Vásquez, Ximena ; García-Zamora, Elena ; López-Estebaranz, Jose Luis</creatorcontrib><description>Nivolumab, a monoclonal antibody against the programmed cell death protein 1 (PD-1), has shown promising results in patients with advanced malignancies, including melanoma, lung cancer, and renal cancer. Immune-related adverse events (irAEs) have been reported, including both organ-specific toxicities and skin toxicities. Herein, we report a case of predominantly palmoplantar psoriasis with severe nail involvement, psoriatic arthritis, and autoimmune hypothyroidism after receiving nivolumab treatment for lung cancer. We also summarize the case reports that have been published previously. The knowledge of these irAEs in patients undergoing anti-PD1 therapy is important since it will enable earlier recognition and appropriate management, with the aim of maintaining effective dose without disruption.</description><identifier>ISSN: 1087-2108</identifier><identifier>EISSN: 1087-2108</identifier><identifier>DOI: 10.5070/D3238036018</identifier><identifier>PMID: 29469753</identifier><language>eng</language><publisher>United States</publisher><ispartof>Dermatology online journal, 2017-08, Vol.23 (8)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2418-364f69fb47e005441402aadddaf96c93dcebf06c2c8ffd9053ab699f730e49363</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29469753$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Elosua-González, Marta</creatorcontrib><creatorcontrib>Pampín-Franco, Ana</creatorcontrib><creatorcontrib>Mazzucchelli-Esteban, Ramón</creatorcontrib><creatorcontrib>Mielgo-Rubio, Xabier</creatorcontrib><creatorcontrib>Rodriguez-Vásquez, Ximena</creatorcontrib><creatorcontrib>García-Zamora, Elena</creatorcontrib><creatorcontrib>López-Estebaranz, Jose Luis</creatorcontrib><title>A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy</title><title>Dermatology online journal</title><addtitle>Dermatol Online J</addtitle><description>Nivolumab, a monoclonal antibody against the programmed cell death protein 1 (PD-1), has shown promising results in patients with advanced malignancies, including melanoma, lung cancer, and renal cancer. Immune-related adverse events (irAEs) have been reported, including both organ-specific toxicities and skin toxicities. Herein, we report a case of predominantly palmoplantar psoriasis with severe nail involvement, psoriatic arthritis, and autoimmune hypothyroidism after receiving nivolumab treatment for lung cancer. We also summarize the case reports that have been published previously. The knowledge of these irAEs in patients undergoing anti-PD1 therapy is important since it will enable earlier recognition and appropriate management, with the aim of maintaining effective dose without disruption.</description><issn>1087-2108</issn><issn>1087-2108</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpNkMlLxTAQh4Mo7ifvkqMgT6dJuuQo7iB40XOZZrGRtqlJ-uQd_c-tvKd4mYX5-MF8hJxkcJFDCZc3nPEKeAFZtUX2M6jKBZvr9r95jxzE-A7AQOR8l-wxKQpZ5nyffF1RhdFQb6k2dPBLT0fsej92OCQMdIw-OIwu0k-X2s2anKIYUhtcmg84aIpT8q7vp8HQdjX61K6Cd9rFnqJNJtBglHFLN7zRwS19N_XY0NSagOPqiOxY7KI53vRD8np3-3L9sHh6vn-8vnpaKCayasELYQtpG1EagFyITABD1FqjlYWSXCvTWCgUU5W1WkLOsSmktCUHIyQv-CE5W-eOwX9MJqa6d1GZbn7U-CnWDKAULKtyPqPna1QFH2Mwth6D6zGs6gzqH-f1P-czfboJnpre6D_2VzL_Bkqzfv0</recordid><startdate>20170815</startdate><enddate>20170815</enddate><creator>Elosua-González, Marta</creator><creator>Pampín-Franco, Ana</creator><creator>Mazzucchelli-Esteban, Ramón</creator><creator>Mielgo-Rubio, Xabier</creator><creator>Rodriguez-Vásquez, Ximena</creator><creator>García-Zamora, Elena</creator><creator>López-Estebaranz, Jose Luis</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170815</creationdate><title>A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy</title><author>Elosua-González, Marta ; Pampín-Franco, Ana ; Mazzucchelli-Esteban, Ramón ; Mielgo-Rubio, Xabier ; Rodriguez-Vásquez, Ximena ; García-Zamora, Elena ; López-Estebaranz, Jose Luis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2418-364f69fb47e005441402aadddaf96c93dcebf06c2c8ffd9053ab699f730e49363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elosua-González, Marta</creatorcontrib><creatorcontrib>Pampín-Franco, Ana</creatorcontrib><creatorcontrib>Mazzucchelli-Esteban, Ramón</creatorcontrib><creatorcontrib>Mielgo-Rubio, Xabier</creatorcontrib><creatorcontrib>Rodriguez-Vásquez, Ximena</creatorcontrib><creatorcontrib>García-Zamora, Elena</creatorcontrib><creatorcontrib>López-Estebaranz, Jose Luis</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Dermatology online journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elosua-González, Marta</au><au>Pampín-Franco, Ana</au><au>Mazzucchelli-Esteban, Ramón</au><au>Mielgo-Rubio, Xabier</au><au>Rodriguez-Vásquez, Ximena</au><au>García-Zamora, Elena</au><au>López-Estebaranz, Jose Luis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy</atitle><jtitle>Dermatology online journal</jtitle><addtitle>Dermatol Online J</addtitle><date>2017-08-15</date><risdate>2017</risdate><volume>23</volume><issue>8</issue><issn>1087-2108</issn><eissn>1087-2108</eissn><abstract>Nivolumab, a monoclonal antibody against the programmed cell death protein 1 (PD-1), has shown promising results in patients with advanced malignancies, including melanoma, lung cancer, and renal cancer. Immune-related adverse events (irAEs) have been reported, including both organ-specific toxicities and skin toxicities. Herein, we report a case of predominantly palmoplantar psoriasis with severe nail involvement, psoriatic arthritis, and autoimmune hypothyroidism after receiving nivolumab treatment for lung cancer. We also summarize the case reports that have been published previously. The knowledge of these irAEs in patients undergoing anti-PD1 therapy is important since it will enable earlier recognition and appropriate management, with the aim of maintaining effective dose without disruption.</abstract><cop>United States</cop><pmid>29469753</pmid><doi>10.5070/D3238036018</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-2108 |
| ispartof | Dermatology online journal, 2017-08, Vol.23 (8) |
| issn | 1087-2108 1087-2108 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2007421853 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| title | A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T05%3A16%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20case%20of%20de%20novo%20palmoplantar%20psoriasis%20with%20psoriatic%20arthritis%20and%20autoimmune%20hypothyroidism%20after%20receiving%20nivolumab%20therapy&rft.jtitle=Dermatology%20online%20journal&rft.au=Elosua-Gonz%C3%A1lez,%20Marta&rft.date=2017-08-15&rft.volume=23&rft.issue=8&rft.issn=1087-2108&rft.eissn=1087-2108&rft_id=info:doi/10.5070/D3238036018&rft_dat=%3Cproquest_cross%3E2007421853%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2007421853&rft_id=info:pmid/29469753&rfr_iscdi=true |